Industry Research Reports
Global Peptide Therapeutics Market Research Report 2026
Industry: Medical Care
Published Date: 2026-02-14
Pages: 131 Pages
Report ld: 5533027
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Peptide Therapeutics Market Size(US$)
CAGR 2026-2032
9.0%
Market Size,2032
USD 80,340
Million
Market Snapshot
Market Size in 2026 (Value)
US$ 47,910 million
Market Forecast in 2032(Value)
US$ 80,340 million
CAGR
9.0%
Years Considered
2021-2032
Base Year
2026
Forecast Period
2026-2032
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Peptide Therapeutics market was valued at US$ 44320 million in 2025 and is anticipated to reach US$ 80340 million by 2032, at a CAGR of 9.0% from 2026 to 2032.
Peptide therapeutics are a class of pharmaceutical drugs composed of short chains of amino acids, typically ranging from 2 to 50 residues, that mimic natural peptides in the body. These drugs are designed to interact with specific cellular targets, such as receptors, enzymes, or ion channels, to regulate physiological functions. Due to their high specificity, low toxicity, and favorable safety profiles, peptide drugs are widely used in the treatment of various diseases, including cancer, diabetes, cardiovascular diseases, and infectious conditions. With advances in peptide engineering, formulation, and delivery technologies, peptide therapeutics have become a growing segment of the biopharmaceutical industry.The average gross profit margin of this product is 70%.
The Peptide Therapeutics market is driven by the increasing demand for highly specific and efficient treatments for a wide range of diseases, including cancer, diabetes, cardiovascular conditions, and rare genetic disorders. Peptides, due to their high selectivity, low immunogenicity, and close resemblance to natural biological molecules, are well-suited for targeted therapy with fewer side effects. Technological advancements in peptide synthesis, modification, and drug delivery systems have enhanced their stability and extended their half-life, making them more viable for clinical use. Additionally, the growing investment in biopharmaceutical research and development, along with a favorable regulatory environment for innovative therapies, is accelerating the development and approval of peptide-based drugs.
Despite these advantages, the Peptide Therapeutics market faces several challenges, particularly related to drug delivery and manufacturing. Peptides are generally unstable in the gastrointestinal tract and are rapidly degraded by enzymes, limiting their oral bioavailability and often requiring parenteral administration. This can affect patient compliance and limit market penetration. Moreover, the complex and costly manufacturing processes for peptide drugs, including synthesis, purification, and formulation, pose economic and technical barriers, especially for smaller biotech firms. Overcoming these limitations through innovative formulation strategies and cost-efficient production methods is critical for ensuring broader clinical adoption and long-term market growth.
This report delivers a comprehensive overview of the global Peptide Therapeutics market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Peptide Therapeutics. The Peptide Therapeutics market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Peptide Therapeutics market comprehensively. Regional market sizes by Type, by Application, by Target Class, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Peptide Therapeutics manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
MARKET SEGMENTATION
By Company
- Sanofi
- Teva
- Novo Nordisk
- Takeda
- Eli Lilly
- AstraZeneca
- Novartis
- AbbVie
- Ipsen
- Ferring
- Merck
- The Medicines
- J & J
- Aurinia Pharmaceuticals
- BioMarin Pharmaceutical
- Apellis Pharmaceuticals
- Lantheus
- CSL Vifor Group
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Injection
- Oral
- Other
Segment by Application
- Cancer
- Metabolic Disorders
- Central Nervous System
- Other
Segment by Category
- Agonist/Analog
- Antagonist
- Enzyme Inhibitor
- Ion Channel
Segment by Division
- Retail
- Hospital
- Other
CHAPTER OUTLINE
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Target Class, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Peptide Therapeutics companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide Therapeutics Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Injection
1.2.3 Oral
1.2.4 Other
1.3 Market by Target Class
1.3.1 Global Peptide Therapeutics Market Size Growth Rate by Target Class: 2021 vs 2025 vs 2032
1.3.2 Agonist/Analog
1.3.3 Antagonist
1.3.4 Enzyme Inhibitor
1.3.5 Ion Channel
1.4 Market by End Users
1.4.1 Global Peptide Therapeutics Market Size Growth Rate by End Users: 2021 vs 2025 vs 2032
1.4.2 Retail
1.4.3 Hospital
1.4.4 Other
1.5 Market by Application
1.5.1 Global Peptide Therapeutics Market Growth by Application: 2021 vs 2025 vs 2032
1.5.2 Cancer
1.5.3 Metabolic Disorders
1.5.4 Central Nervous System
1.5.5 Other
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends
2.1 Global Peptide Therapeutics Market Perspective (2021–2032)
2.2 Global Peptide Therapeutics Growth Trends by Region
2.2.1 Global Peptide Therapeutics Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Peptide Therapeutics Historic Market Size by Region (2021–2026)
2.2.3 Peptide Therapeutics Forecasted Market Size by Region (2027–2032)
2.3 Peptide Therapeutics Market Dynamics
2.3.1 Peptide Therapeutics Industry Trends
2.3.2 Peptide Therapeutics Market Drivers
2.3.3 Peptide Therapeutics Market Challenges
2.3.4 Peptide Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide Therapeutics Players by Revenue
3.1.1 Global Top Peptide Therapeutics Players by Revenue (2021–2026)
3.1.2 Global Peptide Therapeutics Revenue Market Share by Players (2021–2026)
3.2 Global Top Peptide Therapeutics Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Peptide Therapeutics Revenue
3.4 Global Peptide Therapeutics Market Concentration Ratio
3.4.1 Global Peptide Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide Therapeutics Revenue in 2025
3.5 Global Key Players of Peptide Therapeutics Head Offices and Areas Served
3.6 Global Key Players of Peptide Therapeutics, Products and Applications
3.7 Global Key Players of Peptide Therapeutics, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Peptide Therapeutics Breakdown Data by Type
4.1 Global Peptide Therapeutics Historic Market Size by Type (2021–2026)
4.2 Global Peptide Therapeutics Forecasted Market Size by Type (2027–2032)
5 Peptide Therapeutics Breakdown Data by Application
5.1 Global Peptide Therapeutics Historic Market Size by Application (2021–2026)
5.2 Global Peptide Therapeutics Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Peptide Therapeutics Market Size (2021–2032)
6.2 North America Peptide Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Peptide Therapeutics Market Size by Country (2021–2026)
6.4 North America Peptide Therapeutics Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peptide Therapeutics Market Size (2021–2032)
7.2 Europe Peptide Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Peptide Therapeutics Market Size by Country (2021–2026)
7.4 Europe Peptide Therapeutics Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Peptide Therapeutics Market Size (2021–2032)
8.2 Asia-Pacific Peptide Therapeutics Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Peptide Therapeutics Market Size by Region (2021–2026)
8.4 Asia-Pacific Peptide Therapeutics Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Peptide Therapeutics Market Size (2021–2032)
9.2 Latin America Peptide Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Peptide Therapeutics Market Size by Country (2021–2026)
9.4 Latin America Peptide Therapeutics Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide Therapeutics Market Size (2021–2032)
10.2 Middle East & Africa Peptide Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Peptide Therapeutics Market Size by Country (2021–2026)
10.4 Middle East & Africa Peptide Therapeutics Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Peptide Therapeutics Introduction
11.1.4 Sanofi Revenue in Peptide Therapeutics Business (2021–2026)
11.1.5 Sanofi Recent Development
11.2 Teva
11.2.1 Teva Company Details
11.2.2 Teva Business Overview
11.2.3 Teva Peptide Therapeutics Introduction
11.2.4 Teva Revenue in Peptide Therapeutics Business (2021–2026)
11.2.5 Teva Recent Development
11.3 Novo Nordisk
11.3.1 Novo Nordisk Company Details
11.3.2 Novo Nordisk Business Overview
11.3.3 Novo Nordisk Peptide Therapeutics Introduction
11.3.4 Novo Nordisk Revenue in Peptide Therapeutics Business (2021–2026)
11.3.5 Novo Nordisk Recent Development
11.4 Takeda
11.4.1 Takeda Company Details
11.4.2 Takeda Business Overview
11.4.3 Takeda Peptide Therapeutics Introduction
11.4.4 Takeda Revenue in Peptide Therapeutics Business (2021–2026)
11.4.5 Takeda Recent Development
11.5 Eli Lilly
11.5.1 Eli Lilly Company Details
11.5.2 Eli Lilly Business Overview
11.5.3 Eli Lilly Peptide Therapeutics Introduction
11.5.4 Eli Lilly Revenue in Peptide Therapeutics Business (2021–2026)
11.5.5 Eli Lilly Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Details
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Peptide Therapeutics Introduction
11.6.4 AstraZeneca Revenue in Peptide Therapeutics Business (2021–2026)
11.6.5 AstraZeneca Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Peptide Therapeutics Introduction
11.7.4 Novartis Revenue in Peptide Therapeutics Business (2021–2026)
11.7.5 Novartis Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Details
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Peptide Therapeutics Introduction
11.8.4 AbbVie Revenue in Peptide Therapeutics Business (2021–2026)
11.8.5 AbbVie Recent Development
11.9 Ipsen
11.9.1 Ipsen Company Details
11.9.2 Ipsen Business Overview
11.9.3 Ipsen Peptide Therapeutics Introduction
11.9.4 Ipsen Revenue in Peptide Therapeutics Business (2021–2026)
11.9.5 Ipsen Recent Development
11.10 Ferring
11.10.1 Ferring Company Details
11.10.2 Ferring Business Overview
11.10.3 Ferring Peptide Therapeutics Introduction
11.10.4 Ferring Revenue in Peptide Therapeutics Business (2021–2026)
11.10.5 Ferring Recent Development
11.11 Merck
11.11.1 Merck Company Details
11.11.2 Merck Business Overview
11.11.3 Merck Peptide Therapeutics Introduction
11.11.4 Merck Revenue in Peptide Therapeutics Business (2021–2026)
11.11.5 Merck Recent Development
11.12 The Medicines
11.12.1 The Medicines Company Details
11.12.2 The Medicines Business Overview
11.12.3 The Medicines Peptide Therapeutics Introduction
11.12.4 The Medicines Revenue in Peptide Therapeutics Business (2021–2026)
11.12.5 The Medicines Recent Development
11.13 J & J
11.13.1 J & J Company Details
11.13.2 J & J Business Overview
11.13.3 J & J Peptide Therapeutics Introduction
11.13.4 J & J Revenue in Peptide Therapeutics Business (2021–2026)
11.13.5 J & J Recent Development
11.14 Aurinia Pharmaceuticals
11.14.1 Aurinia Pharmaceuticals Company Details
11.14.2 Aurinia Pharmaceuticals Business Overview
11.14.3 Aurinia Pharmaceuticals Peptide Therapeutics Introduction
11.14.4 Aurinia Pharmaceuticals Revenue in Peptide Therapeutics Business (2021–2026)
11.14.5 Aurinia Pharmaceuticals Recent Development
11.15 BioMarin Pharmaceutical
11.15.1 BioMarin Pharmaceutical Company Details
11.15.2 BioMarin Pharmaceutical Business Overview
11.15.3 BioMarin Pharmaceutical Peptide Therapeutics Introduction
11.15.4 BioMarin Pharmaceutical Revenue in Peptide Therapeutics Business (2021–2026)
11.15.5 BioMarin Pharmaceutical Recent Development
11.16 Apellis Pharmaceuticals
11.16.1 Apellis Pharmaceuticals Company Details
11.16.2 Apellis Pharmaceuticals Business Overview
11.16.3 Apellis Pharmaceuticals Peptide Therapeutics Introduction
11.16.4 Apellis Pharmaceuticals Revenue in Peptide Therapeutics Business (2021–2026)
11.16.5 Apellis Pharmaceuticals Recent Development
11.17 Lantheus
11.17.1 Lantheus Company Details
11.17.2 Lantheus Business Overview
11.17.3 Lantheus Peptide Therapeutics Introduction
11.17.4 Lantheus Revenue in Peptide Therapeutics Business (2021–2026)
11.17.5 Lantheus Recent Development
11.18 CSL Vifor Group
11.18.1 CSL Vifor Group Company Details
11.18.2 CSL Vifor Group Business Overview
11.18.3 CSL Vifor Group Peptide Therapeutics Introduction
11.18.4 CSL Vifor Group Revenue in Peptide Therapeutics Business (2021–2026)
11.18.5 CSL Vifor Group Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Global Peptide Therapeutics Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Injection
Table 3. Key Players of Oral
Table 4. Key Players of Other
Table 5. Global Peptide Therapeutics Market Size Growth Rate by Target Class (US$ Million): 2021 vs 2025 vs 2032
Table 6. Key Players of Agonist/Analog
Table 7. Key Players of Antagonist
Table 8. Key Players of Enzyme Inhibitor
Table 9. Key Players of Ion Channel
Table 10. Global Peptide Therapeutics Market Size Growth Rate by End Users (US$ Million): 2021 vs 2025 vs 2032
Table 11. Key Players of Retail
Table 12. Key Players of Hospital
Table 13. Key Players of Other
Table 14. Global Peptide Therapeutics Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 15. Global Peptide Therapeutics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 16. Global Peptide Therapeutics Market Size by Region (US$ Million), 2021–2026
Table 17. Global Peptide Therapeutics Market Share by Region (2021–2026)
Table 18. Global Peptide Therapeutics Forecasted Market Size by Region (US$ Million), 2027–2032
Table 19. Global Peptide Therapeutics Market Share by Region (2027–2032)
Table 20. Peptide Therapeutics Market Trends
Table 21. Peptide Therapeutics Market Drivers
Table 22. Peptide Therapeutics Market Challenges
Table 23. Peptide Therapeutics Market Restraints
Table 24. Global Peptide Therapeutics Revenue by Players (US$ Million), 2021–2026
Table 25. Global Peptide Therapeutics Market Share by Players (2021–2026)
Table 26. Global Top Peptide Therapeutics Players by Tier (Tier 1, Tier 2, and Tier 3), based on Peptide Therapeutics Revenue, 2025
Table 27. Ranking of Global Top Peptide Therapeutics Companies by Revenue (US$ Million) in 2025
Table 28. Global 5 Largest Players Market Share by Peptide Therapeutics Revenue (CR5 and HHI), 2021–2026
Table 29. Global Key Players of Peptide Therapeutics, Headquarters and Area Served
Table 30. Global Key Players of Peptide Therapeutics, Products and Applications
Table 31. Global Key Players of Peptide Therapeutics, Date of General Availability (GA)
Table 32. Mergers and Acquisitions, Expansion Plans
Table 33. Global Peptide Therapeutics Market Size by Type (US$ Million), 2021–2026
Table 34. Global Peptide Therapeutics Revenue Market Share by Type (2021–2026)
Table 35. Global Peptide Therapeutics Forecasted Market Size by Type (US$ Million), 2027–2032
Table 36. Global Peptide Therapeutics Revenue Market Share by Type (2027–2032)
Table 37. Global Peptide Therapeutics Market Size by Application (US$ Million), 2021–2026
Table 38. Global Peptide Therapeutics Revenue Market Share by Application (2021–2026)
Table 39. Global Peptide Therapeutics Forecasted Market Size by Application (US$ Million), 2027–2032
Table 40. Global Peptide Therapeutics Revenue Market Share by Application (2027–2032)
Table 41. North America Peptide Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 42. North America Peptide Therapeutics Market Size by Country (US$ Million), 2021–2026
Table 43. North America Peptide Therapeutics Market Size by Country (US$ Million), 2027–2032
Table 44. Europe Peptide Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 45. Europe Peptide Therapeutics Market Size by Country (US$ Million), 2021–2026
Table 46. Europe Peptide Therapeutics Market Size by Country (US$ Million), 2027–2032
Table 47. Asia-Pacific Peptide Therapeutics Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 48. Asia-Pacific Peptide Therapeutics Market Size by Region (US$ Million), 2021–2026
Table 49. Asia-Pacific Peptide Therapeutics Market Size by Region (US$ Million), 2027–2032
Table 50. Latin America Peptide Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 51. Latin America Peptide Therapeutics Market Size by Country (US$ Million), 2021–2026
Table 52. Latin America Peptide Therapeutics Market Size by Country (US$ Million), 2027–2032
Table 53. Middle East & Africa Peptide Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 54. Middle East & Africa Peptide Therapeutics Market Size by Country (US$ Million), 2021–2026
Table 55. Middle East & Africa Peptide Therapeutics Market Size by Country (US$ Million), 2027–2032
Table 56. Sanofi Company Details
Table 57. Sanofi Business Overview
Table 58. Sanofi Peptide Therapeutics Product
Table 59. Sanofi Revenue in Peptide Therapeutics Business (US$ Million), 2021–2026
Table 60. Sanofi Recent Development
Table 61. Teva Company Details
Table 62. Teva Business Overview
Table 63. Teva Peptide Therapeutics Product
Table 64. Teva Revenue in Peptide Therapeutics Business (US$ Million), 2021–2026
Table 65. Teva Recent Development
Table 66. Novo Nordisk Company Details
Table 67. Novo Nordisk Business Overview
Table 68. Novo Nordisk Peptide Therapeutics Product
Table 69. Novo Nordisk Revenue in Peptide Therapeutics Business (US$ Million), 2021–2026
Table 70. Novo Nordisk Recent Development
Table 71. Takeda Company Details
Table 72. Takeda Business Overview
Table 73. Takeda Peptide Therapeutics Product
Table 74. Takeda Revenue in Peptide Therapeutics Business (US$ Million), 2021–2026
Table 75. Takeda Recent Development
Table 76. Eli Lilly Company Details
Table 77. Eli Lilly Business Overview
Table 78. Eli Lilly Peptide Therapeutics Product
Table 79. Eli Lilly Revenue in Peptide Therapeutics Business (US$ Million), 2021–2026
Table 80. Eli Lilly Recent Development
Table 81. AstraZeneca Company Details
Table 82. AstraZeneca Business Overview
Table 83. AstraZeneca Peptide Therapeutics Product
Table 84. AstraZeneca Revenue in Peptide Therapeutics Business (US$ Million), 2021–2026
Table 85. AstraZeneca Recent Development
Table 86. Novartis Company Details
Table 87. Novartis Business Overview
Table 88. Novartis Peptide Therapeutics Product
Table 89. Novartis Revenue in Peptide Therapeutics Business (US$ Million), 2021–2026
Table 90. Novartis Recent Development
Table 91. AbbVie Company Details
Table 92. AbbVie Business Overview
Table 93. AbbVie Peptide Therapeutics Product
Table 94. AbbVie Revenue in Peptide Therapeutics Business (US$ Million), 2021–2026
Table 95. AbbVie Recent Development
Table 96. Ipsen Company Details
Table 97. Ipsen Business Overview
Table 98. Ipsen Peptide Therapeutics Product
Table 99. Ipsen Revenue in Peptide Therapeutics Business (US$ Million), 2021–2026
Table 100. Ipsen Recent Development
Table 101. Ferring Company Details
Table 102. Ferring Business Overview
Table 103. Ferring Peptide Therapeutics Product
Table 104. Ferring Revenue in Peptide Therapeutics Business (US$ Million), 2021–2026
Table 105. Ferring Recent Development
Table 106. Merck Company Details
Table 107. Merck Business Overview
Table 108. Merck Peptide Therapeutics Product
Table 109. Merck Revenue in Peptide Therapeutics Business (US$ Million), 2021–2026
Table 110. Merck Recent Development
Table 111. The Medicines Company Details
Table 112. The Medicines Business Overview
Table 113. The Medicines Peptide Therapeutics Product
Table 114. The Medicines Revenue in Peptide Therapeutics Business (US$ Million), 2021–2026
Table 115. The Medicines Recent Development
Table 116. J & J Company Details
Table 117. J & J Business Overview
Table 118. J & J Peptide Therapeutics Product
Table 119. J & J Revenue in Peptide Therapeutics Business (US$ Million), 2021–2026
Table 120. J & J Recent Development
Table 121. Aurinia Pharmaceuticals Company Details
Table 122. Aurinia Pharmaceuticals Business Overview
Table 123. Aurinia Pharmaceuticals Peptide Therapeutics Product
Table 124. Aurinia Pharmaceuticals Revenue in Peptide Therapeutics Business (US$ Million), 2021–2026
Table 125. Aurinia Pharmaceuticals Recent Development
Table 126. BioMarin Pharmaceutical Company Details
Table 127. BioMarin Pharmaceutical Business Overview
Table 128. BioMarin Pharmaceutical Peptide Therapeutics Product
Table 129. BioMarin Pharmaceutical Revenue in Peptide Therapeutics Business (US$ Million), 2021–2026
Table 130. BioMarin Pharmaceutical Recent Development
Table 131. Apellis Pharmaceuticals Company Details
Table 132. Apellis Pharmaceuticals Business Overview
Table 133. Apellis Pharmaceuticals Peptide Therapeutics Product
Table 134. Apellis Pharmaceuticals Revenue in Peptide Therapeutics Business (US$ Million), 2021–2026
Table 135. Apellis Pharmaceuticals Recent Development
Table 136. Lantheus Company Details
Table 137. Lantheus Business Overview
Table 138. Lantheus Peptide Therapeutics Product
Table 139. Lantheus Revenue in Peptide Therapeutics Business (US$ Million), 2021–2026
Table 140. Lantheus Recent Development
Table 141. CSL Vifor Group Company Details
Table 142. CSL Vifor Group Business Overview
Table 143. CSL Vifor Group Peptide Therapeutics Product
Table 144. CSL Vifor Group Revenue in Peptide Therapeutics Business (US$ Million), 2021–2026
Table 145. CSL Vifor Group Recent Development
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
Table 149. Authors List of This Report
List of Figures
Figure 1. Peptide Therapeutics Picture
Figure 2. Global Peptide Therapeutics Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Peptide Therapeutics Market Share by Type: 2025 vs 2032
Figure 4. Injection Features
Figure 5. Oral Features
Figure 6. Other Features
Figure 7. Global Peptide Therapeutics Market Size Comparison by Target Class (US$ Million), 2021–2032
Figure 8. Agonist/Analog Features
Figure 9. Antagonist Features
Figure 10. Enzyme Inhibitor Features
Figure 11. Ion Channel Features
Figure 12. Global Peptide Therapeutics Market Size Comparison by End Users (US$ Million), 2021–2032
Figure 13. Retail Features
Figure 14. Hospital Features
Figure 15. Other Features
Figure 16. Global Peptide Therapeutics Market Size by Application (US$ Million), 2021–2032
Figure 17. Global Peptide Therapeutics Market Share by Application: 2025 vs 2032
Figure 18. Cancer Case Studies
Figure 19. Metabolic Disorders Case Studies
Figure 20. Central Nervous System Case Studies
Figure 21. Other Case Studies
Figure 22. Peptide Therapeutics Report Years Considered
Figure 23. Global Peptide Therapeutics Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 24. Global Peptide Therapeutics Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 25. Global Peptide Therapeutics Market Share by Region: 2025 vs 2032
Figure 26. Global Peptide Therapeutics Market Share by Players in 2025
Figure 27. Global Peptide Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 28. The Top 10 and 5 Players Market Share by Peptide Therapeutics Revenue in 2025
Figure 29. North America Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. North America Peptide Therapeutics Market Share by Country (2021–2032)
Figure 31. United States Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Canada Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Europe Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Europe Peptide Therapeutics Market Share by Country (2021–2032)
Figure 35. Germany Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. France Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. U.K. Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Italy Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Russia Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Ireland Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Asia-Pacific Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Asia-Pacific Peptide Therapeutics Market Share by Region (2021–2032)
Figure 43. China Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Japan Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. South Korea Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Southeast Asia Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. India Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Australia & New Zealand Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Latin America Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. Latin America Peptide Therapeutics Market Share by Country (2021–2032)
Figure 51. Mexico Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 52. Brazil Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 53. Middle East & Africa Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 54. Middle East & Africa Peptide Therapeutics Market Share by Country (2021–2032)
Figure 55. Israel Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 56. Saudi Arabia Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 57. UAE Peptide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032
Figure 58. Sanofi Revenue Growth Rate in Peptide Therapeutics Business (2021–2026)
Figure 59. Teva Revenue Growth Rate in Peptide Therapeutics Business (2021–2026)
Figure 60. Novo Nordisk Revenue Growth Rate in Peptide Therapeutics Business (2021–2026)
Figure 61. Takeda Revenue Growth Rate in Peptide Therapeutics Business (2021–2026)
Figure 62. Eli Lilly Revenue Growth Rate in Peptide Therapeutics Business (2021–2026)
Figure 63. AstraZeneca Revenue Growth Rate in Peptide Therapeutics Business (2021–2026)
Figure 64. Novartis Revenue Growth Rate in Peptide Therapeutics Business (2021–2026)
Figure 65. AbbVie Revenue Growth Rate in Peptide Therapeutics Business (2021–2026)
Figure 66. Ipsen Revenue Growth Rate in Peptide Therapeutics Business (2021–2026)
Figure 67. Ferring Revenue Growth Rate in Peptide Therapeutics Business (2021–2026)
Figure 68. Merck Revenue Growth Rate in Peptide Therapeutics Business (2021–2026)
Figure 69. The Medicines Revenue Growth Rate in Peptide Therapeutics Business (2021–2026)
Figure 70. J & J Revenue Growth Rate in Peptide Therapeutics Business (2021–2026)
Figure 71. Aurinia Pharmaceuticals Revenue Growth Rate in Peptide Therapeutics Business (2021–2026)
Figure 72. BioMarin Pharmaceutical Revenue Growth Rate in Peptide Therapeutics Business (2021–2026)
Figure 73. Apellis Pharmaceuticals Revenue Growth Rate in Peptide Therapeutics Business (2021–2026)
Figure 74. Lantheus Revenue Growth Rate in Peptide Therapeutics Business (2021–2026)
Figure 75. CSL Vifor Group Revenue Growth Rate in Peptide Therapeutics Business (2021–2026)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
What was the global market size of Peptide Therapeutics in 2026?
The global market size of Peptide Therapeutics in 2026 was 47910 Million USD.
What was the global market size of Peptide Therapeutics in 2032?
Which companies rank high in the global Peptide Therapeutics market?
Which region is expected to have the highest market share?
What is the annual compound growth rate of the global Peptide Therapeutics market size from 2026 to 2032?
Related Reports
Global Peptide Therapeutics Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Peptide Therapeutics market is projected to grow from US$ 44320 million in 2025 to US$ 80340 million by 2032, at a CAGR of 9.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-02-14
Pages: 152
USD 4900.00
(Single User License)
Global Peptide Therapeutics Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Peptide Therapeutics market size was US$ 44320 million in 2025 and is forecast to reach a readjusted size of US$ 80340 million by 2032 with a CAGR of 9.0% during the forecast period 2026-2032.
Published Date: 2026-02-14
Pages: 108
USD 4250.00
(Single User License)
Peptide Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Peptide Therapeutics was estimated to be worth US$ 44320 million in 2025 and is projected to reach US$ 80340 million, growing at a CAGR of 9.0% from 2026 to 2032.
Published Date: 2026-02-14
Pages: 122
USD 3950.00
(Single User License)
Global Peptide Therapeutics Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Peptide Therapeutics market is projected to grow from US$ 41000 million in 2024 to US$ 74320 million by 2031, at a CAGR of 9.0% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-09-11
Pages: 151
USD 4900.00
(Single User License)
Peptide Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Peptide Therapeutics was estimated to be worth US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published Date: 2025-05-24
Pages: 139
USD 3950.00
(Single User License)
Global Peptide Therapeutics Market Insights, Forecast to 2031
The global Peptide Therapeutics market is projected to grow from US$ 44320 million in 2025 to US$ 74320 million by 2031, at a Compound Annual Growth Rate (CAGR) of 9.0% during the forecast period.
Published Date: 2025-05-24
Pages: 158
USD 4900.00
(Single User License)
Global Peptide Therapeutics Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Peptide Therapeutics market size was US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published Date: 2025-05-24
Pages: 110
USD 4250.00
(Single User License)
Global Peptide Therapeutics Market Research Report 2025
The global market for Peptide Therapeutics was valued at US$ 41000 million in the year 2024 and is projected to reach a revised size of US$ 74320 million by 2031, growing at a CAGR of 9.0% during the forecast period.
Published Date: 2025-05-24
Pages: 94
USD 2900.00
(Single User License)
Global Peptide Therapeutics Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Peptide Therapeutics was estimated to be worth US$ 41000 million and is forecast to reach approximately US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published Date: 2025-03-28
Pages: 143
USD 5900.00
(Single User License)
Peptide Therapeutics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Peptide Therapeutics was estimated to be worth US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 120
USD 3950.00
(Single User License)
Global Peptide Therapeutics Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Peptide Therapeutics market is projected to grow from US$ 44320 million in 2025 to US$ 80340 million by 2032, at a CAGR of 9.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-02-14
Pages: 152
USD 4900.00 (Single User License)Global Peptide Therapeutics Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Peptide Therapeutics market size was US$ 44320 million in 2025 and is forecast to reach a readjusted size of US$ 80340 million by 2032 with a CAGR of 9.0% during the forecast period 2026-2032.
Published: 2026-02-14
Pages: 108
USD 4250.00 (Single User License)Peptide Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Peptide Therapeutics was estimated to be worth US$ 44320 million in 2025 and is projected to reach US$ 80340 million, growing at a CAGR of 9.0% from 2026 to 2032.
Published: 2026-02-14
Pages: 122
USD 3950.00 (Single User License)Global Peptide Therapeutics Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Peptide Therapeutics market is projected to grow from US$ 41000 million in 2024 to US$ 74320 million by 2031, at a CAGR of 9.0% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-09-11
Pages: 151
USD 4900.00 (Single User License)Peptide Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Peptide Therapeutics was estimated to be worth US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published: 2025-05-24
Pages: 139
USD 3950.00 (Single User License)Global Peptide Therapeutics Market Insights, Forecast to 2031
The global Peptide Therapeutics market is projected to grow from US$ 44320 million in 2025 to US$ 74320 million by 2031, at a Compound Annual Growth Rate (CAGR) of 9.0% during the forecast period.
Published: 2025-05-24
Pages: 158
USD 4900.00 (Single User License)Global Peptide Therapeutics Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Peptide Therapeutics market size was US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published: 2025-05-24
Pages: 110
USD 4250.00 (Single User License)Global Peptide Therapeutics Market Research Report 2025
The global market for Peptide Therapeutics was valued at US$ 41000 million in the year 2024 and is projected to reach a revised size of US$ 74320 million by 2031, growing at a CAGR of 9.0% during the forecast period.
Published: 2025-05-24
Pages: 94
USD 2900.00 (Single User License)Global Peptide Therapeutics Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Peptide Therapeutics was estimated to be worth US$ 41000 million and is forecast to reach approximately US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published: 2025-03-28
Pages: 143
USD 5900.00 (Single User License)Peptide Therapeutics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Peptide Therapeutics was estimated to be worth US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 120
USD 3950.00 (Single User License)
CHOOSE LICENSE TYPE
USD 2900.00
USD 4350.00
USD 5800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now